- Previous Close
71.19 - Open
70.92 - Bid 69.73 x 1100
- Ask 72.12 x 1300
- Day's Range
70.64 - 71.66 - 52 Week Range
58.93 - 95.73 - Volume
4,508,493 - Avg. Volume
4,547,405 - Market Cap (intraday)
41.536B - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
30.30 - EPS (TTM)
2.34 - Earnings Date Apr 23, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
80.14
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
www.edwards.comRecent News: EW
View MorePerformance Overview: EW
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EW
View MoreValuation Measures
Market Cap
41.54B
Enterprise Value
38.26B
Trailing P/E
30.30
Forward P/E
29.24
PEG Ratio (5yr expected)
4.26
Price/Sales (ttm)
7.81
Price/Book (mrq)
4.15
Enterprise Value/Revenue
7.03
Enterprise Value/EBITDA
22.20
Financial Highlights
Profitability and Income Statement
Profit Margin
76.75%
Return on Assets (ttm)
8.26%
Return on Equity (ttm)
16.64%
Revenue (ttm)
5.44B
Net Income Avi to Common (ttm)
1.4B
Diluted EPS (ttm)
2.34
Balance Sheet and Cash Flow
Total Cash (mrq)
3.98B
Total Debt/Equity (mrq)
6.96%
Levered Free Cash Flow (ttm)
1.35B